Discuss iRhythm Technologies Inc

Sell iRhythm Technologies Inc

Sell iRhythm Technologies Inc

Buy iRhythm Technologies Inc

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Needham & Company LLC from $151.00 to $130.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $149.00 price target on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Truist Financial Co. from $155.00 to $138.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $110.00 price target on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Truist Financial Co. from $100.00 to $115.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Truist Financial Co. from $115.00 to $133.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Needham & Company LLC from $108.00 to $136.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Needham & Company LLC from $136.00 to $137.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at JPMorgan Chase & Co. from $142.00 to $133.00. They now have an "overweight" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Needham & Company LLC from $137.00 to $138.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $115.00 price target on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Morgan Stanley from $135.00 to $130.00. They now have an "overweight" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Needham & Company LLC from $138.00 to $119.00. They now have a "buy" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $117.00 price target on the stock, down previously from $134.00.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Robert W. Baird from $120.00 to $110.00. They now have an "outperform" rating on the stock.

iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $165.00 to $145.00. They now have an "outperform" rating on the stock.

I'm feeling pretty upbeat about iRhythm Technologies right now. They just reported some solid Q2 results that beat expectations, with 19.3% revenue growth year-over-year. That's nothing to sneeze at! The company seems to be gaining traction in its core markets and is pushing into primary care channels too. Plus, they're on track to launch in four European countries soon and are awaiting a regulatory decision in Japan later this year. Those could be big growth catalysts. The recent upgrade to a Zacks Rank #2 (Buy) is also encouraging. Sure, they're still posting losses, but they've got a hefty cash pile of over $560 million to fund growth. The stock has taken a hit this year, down about 19%, but that could present a buying opportunity if you believe in the long-term story. With strong momentum and multiple catalysts ahead, iRhythm looks well-positioned for future growth. Just keep in mind there are still risks, like potential regulatory hurdles or competition. But overall, I'm cautiously optimistic about iRhythm's prospects.